The Manufacturers Life Insurance Company Increases Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

The Manufacturers Life Insurance Company lifted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 24.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 184,208 shares of the company’s stock after purchasing an additional 36,689 shares during the period. The Manufacturers Life Insurance Company owned about 0.27% of Replimune Group worth $2,019,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of REPL. Quest Partners LLC increased its position in Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares during the last quarter. Algert Global LLC lifted its stake in Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares in the last quarter. Creative Planning grew its holdings in shares of Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its stake in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after buying an additional 5,410 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Price Performance

REPL opened at $12.64 on Tuesday. The company has a 50-day moving average of $12.14 and a 200-day moving average of $10.32. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a market capitalization of $864.83 million, a P/E ratio of -4.14 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities analysts expect that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 8.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REPL. Roth Mkm began coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average price target of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.